A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or General Tonic-clonic Seizures

Trial Profile

A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or General Tonic-clonic Seizures

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Lacosamide (Primary) ; Carbamazepine
  • Indications Partial epilepsies; Tonic-clonic epilepsy
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors UCB
  • Most Recent Events

    • 28 Apr 2017 Results of sub analysis (n=886) stratified by baseline disease severity presented at the 69th Annual Meeting of the American Academy of Neurology
    • 28 Apr 2017 Results of subgroup analysis (n=886) of unclassified patients with initial generalised tonic-clonic seizures were presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 28 Apr 2017 Results of a subgroup analysis assessing safety and efficacy lacosamide monotherapy in elderly patients (n=119), presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top